ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Götze, Silke ^g   Feldhaus, Valeska ^g   Traska, Thilo ^a   Wolter, Marietta ^b   Reifenberger, Guido ^b   Tannapfel, Andrea ^c   Kuhnen, Cornelius ^d   Martin, Dirk ^e   Müller, Oliver ^f   Sievers, Sonja ^g  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d Clemens Hospital Münster   (Germany)

^e Evangelisches Krankenhaus   (Germany)

^f UNIVERSITY OF APPLIED SCIENCES KAISERSLAUTERN   (Germany)

^g MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 5 AZA 2' DEOXYCYTIDINE; BROXURIDINE; ENHANCED GREEN FLUORESCENT PROTEIN; ESOPHAGEAL CANCER RELATED PROTEIN 4; GENE PRODUCT; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; C2ORF40 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; CULTURE MEDIUM; DNA METHYLATION; FLUORESCENCE MICROSCOPY; FUSION GENE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC SCREENING; GENETIC TRANSFECTION; GLIOMA; GOLGI COMPLEX; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MOLECULAR CLONING; PROMOTER REGION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; COLORECTAL TUMOR; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GLIOMA; HUMANS; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC;

EID: 74249095339     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-447     Document Type: Article

References (44)

1. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415-28. 10.1038/nrg962, 12042769.
2. Rodriguez J, Frigola J, Vendrell E, et al. Chromosomal Instability Correlates with Genome-wide DNA Demethylation in Human Primary Colorectal Cancers. Cancer Res 2006, 66:8462-9468. 10.1158/0008-5472.CAN-06-0293, 16951157.
3. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999, 21:163-7. 10.1038/5947, 9988266.
4. Grady WM, Willis J, Guilford PJ, et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 2000, 26:16-7. 10.1038/79120, 10973239.
5. Linhart HG, Lin H, Yamada Y, et al. Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev 2007, 21:3110-22. 10.1101/gad.1594007, 2081977, 18056424.
6. Kanai Y, Ushijima S, Kondo Y, Nakanishi Y, Hirohashi S. DNA methyltransferase expression and DNA methylation of CPG islands and peri-centromeric satellite regions in human colorectal and stomach cancers. Int J Cancer 2001, 91:205-12. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2, 11146446.
7. Widschwendter M, Fiegl H, Egle D, et al. Epigenetic stem cell signature in cancer. Nat Genet 2007, 39:157-8. 10.1038/ng1941, 17200673.
8. Ohm JE, McGarvey KM, Yu X, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007, 39:237-42. 10.1038/ng1972, 2744394, 17211412.
9. Kanai Y, Hirohashi S. Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis 2007, 28:2434-42. 10.1093/carcin/bgm206, 17893234.
10. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001, 61:3225-9.
11. Wales MM, Biel MA, el Deiry W, et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med 1995, 1:570-7. 10.1038/nm0695-570, 7585125.
12. Chen WY, Zeng X, Carter MG, et al. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet 2003, 33:197-202. 10.1038/ng1077, 12539045.
13. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005, 5:223-31. 10.1038/nrc1571, 15719030.
14. Toyota M, Ho C, Ahuja N, et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999, 59:2307-12.
15. Gius D, Cui H, Bradbury CM, et al. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 2004, 6:361-71. 10.1016/j.ccr.2004.08.029, 15488759.
16. Wiencke JK, Zheng S, Morrison Z, Yeh RF. Differentially expressed genes are marked by histone 3 lysine 9 trimethylation in human cancer cells. Oncogene 2008, 27:2412-21. 10.1038/sj.onc.1210895, 17968314.
17. Schmelz K, Sattler N, Wagner M, et al. Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia 2005, 19:103-11.
18. Vanaja DK, Ehrich M, Van den BD, et al. Hypermethylation of Genes for Diagnosis and Risk Stratification of Prostate Cancer. Cancer Invest 2009, 27(5):549-60. 10.1080/07357900802620794, 2693083, 19229700.
19. Yue CM, Deng DJ, Bi MX, Guo LP, Lu SH. Expression of ECRG4, a novel esophageal cancer-related gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma. World J Gastroenterol 2003, 9:1174-8.
20. Li LW, Yu XY, Yang Y, et al. Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo. Int J Cancer 2009, 125:1505-13. 10.1002/ijc.24513, 19521989.
21. Sobin LHWC. TNM classification of malignant tumors 2002, New York: John Wiley & Sons.
22. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109. 10.1007/s00401-007-0243-4, 1929165, 17618441.
23. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990, 215:403-10.
24. Kent WJ. BLAT--the BLAST-like alignment tool. Genome Res 2002, 12:656-64. 187518, 11932250.
25. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002, 18:1427-31. 10.1093/bioinformatics/18.11.1427, 12424112.
26. van den BR, Lesnik Oberstein SA, Ferrari MD, Haan J, van Buchem MA. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: MR imaging findings at different ages--3rd-6th decades. Radiology 2003, 229:683-90. 10.1148/radiol.2293021354, 14593195.
27. Bock C, Reither S, Mikeska T, et al. BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 2005, 21:4067-8. 10.1093/bioinformatics/bti652, 16141249.
28. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 2007, 16(Spec No 1):R50-R59. 10.1093/hmg/ddm018, 17613547.
29. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-8. 10.1038/nature05610, 2712719, 17344846.
30. Su T, Liu H, Lu S. [Cloning and identification of cDNA fragments related to human esophageal cancer]. Zhonghua Zhong Liu Za Zhi 1998, 20:254-7.
31. Mori Y, Ishiguro H, Kuwabara Y, et al. Expression of ECRG4 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma. Oncol Rep 2007, 18:981-5.
32. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007, 120:3163-72. 10.1242/jcs.010389, 17878233.
33. Esteller M. Dormant hypermethylated tumour suppressor genes: questions and answers. J Pathol 2005, 205:172-80. 10.1002/path.1707, 15643671.
34. Mund C, Brueckner B, Lyko F. Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications. Epigenetics 2006, 1:7-13.
35. Mirabeau O, Perlas E, Severini C, et al. Identification of novel peptide hormones in the human proteome by hidden Markov model screening. Genome Res 2007, 17:320-7. 10.1101/gr.5755407, 1800923, 17284679.
36. Lieber M, Smith B, Szakal A, Nelson-Rees W, Todaro G. A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int J Cancer 1976, 17:62-70. 10.1002/ijc.2910170110, 175022.
37. Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 1981, 41:1751-6.
38. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980, 209:497-9. 10.1126/science.6248960, 6248960.
39. Fogh J, Wright WC, Loveless JD. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 1977, 58:209-14.
40. Chen TR, Hay RJ, Macy ML. Intercellular karyotypic similarity in near-diploid cell lines of human tumor origins. Cancer Genet Cytogenet 1983, 10:351-62. 10.1016/0165-4608(83)90092-4, 6652615.
41. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973, 51:1409-16.
42. Leibovitz A, Stinson JC, McCombs WB, et al. Classification of human colorectal adenocarcinoma cell lines. Cancer Res 1976, 36:4562-9.
43. Ponten J, Macintyre EH. Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand 1968, 74:465-86.
44. Stein GH. T98G: an anchorage-independent human tumor cell line that exhibits stationary phase G1 arrest in vitro. J Cell Physiol 1979, 99:43-54. 10.1002/jcp.1040990107, 222778.